Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design

Abstract

Rationale

Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation.

Aim

The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for prevention of new ischemic lesions documented by brain magnetic resonance imaging within 12 months after index stroke.

Design

Prospective, randomized, blinded, parallel-group, open-label, German multicenter phase III trial in approximately 500 patients with embolic stroke of undetermined source. A key inclusion criterion is the presence or the planned implantation of an insertable cardiac monitor. Patients are 1:1 randomized to apixaban or acetylsalicylic acid and treated for a 12-month period. It is an event-driven trial aiming for core-lab adjudicated primary outcome events.

Study outcomes

The primary outcome is the occurrence of at least one new ischemic lesion identified by axial T2-weighted FLAIR magnetic resonance imaging and/or axial DWI magnetic resonance imaging at 12 months when compared with the baseline magnetic resonance imaging. Key secondary outcomes are the combination of recurrent ischemic strokes, hemorrhagic strokes, systemic embolism; combination of MACE including recurrent stroke, myocardial infarction, and cardiovascular death and combination of major and clinically relevant non-major bleeding defined according to ISTH, and change of cognitive function and quality of life (EQ-5D, Stroke Impact Scale).

Discussion

Embolic stroke of undetermined source is caused by embolic disease and associated with a high risk of recurrent ischemic strokes and clinically silent cerebral ischemic lesions. ATTICUS will investigate the impact of atrial fibrillation detected by insertable cardiac monitor and the effects of early anticoagulation with apixaban compared with antiplatelet therapy with acetylsalicylic acid on the incidence of new ischemic lesion after embolic stroke of undetermined source.

Keywords

ESUS stroke atrial fibrillation apixaban NOAC aspirin intracardiac monitor

Get full access to this article

View all access options for this article.

References

Mohr

Thompson

Lazar

et al.

Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–1451.

Sacco

Diener

Yusuf

et al.

PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238–1251.

Hart

Diener

Coutts

et al.

Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429–438.

Lees

Selvarajah

Fenton

et al.

Test accuracy of cognitive screening tests for diagnosis of dementia and multidomain cognitive impairment in stroke. Stroke 2014; 45: 3008–3018.

Golicki

Niewada

Buczek

et al.

Validity of EQ-5D-5L in stroke. Qual Life Res 2014; 6: 1555–1563.

Duncan

Lai

Bode

Perera

DeRosa

. Stroke Impact Scale-16: A brief assessment of physical function. Neurology 2003; 60: 291–296.

Bal

Patel

Almekhlafi

Modi

Demchuk

Coutts

. High rate of magnetic resonance imaging stroke recurrence in cryptogenic transient ischemic attack and minor stroke patients. Stroke 2012; 43: 3387–3388.

Sanna

Diener

Passman

et al.

Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 2478–2486.

Gladstone

Spring

Dorian

et al.

EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 2467–2477.

10.

Poli S, Diedler J, Härtig F, et al. Insertable cardiac monitors after cryptogenic stroke – a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol 2016; 23: 375–381.

11.

Healey

Connolly

Gold

et al.

Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366: 120–129.

12.

Gaita

Corsinovi

Anselmino

et al.

Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. J Am Coll Cardiol 2013; 62: 1990–1997.

13.

Das

Seshadri

Beiser

et al.

Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 2008; 39: 2929–2935.

14.

Cha

M-J

Park

Lee

M-H

et al.

Prevalence of and risk factors for silent ischemic stroke in patients with atrial fibrillation as determined by brain magnetic resonance imaging. Am J Cardiol 2014; 113: 655–661.

15.

Kobayashi

Iguchi

Shimizu

et al.

Silent cerebral infarcts and cerebral white matter lesions in patients with nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis 2012; 21: 310–317.

16.

Marfella

Sasso

Siniscalchi

et al.

Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol 2013; 62: 525–530.

17.

Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM; Rotterdam Scan StudyStroke. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126–1129.

18.

Kang

Lattimore

Latour

Warach

. Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. JAMA Arch Neurol 2006; 63: 1730–1733.

19.

Gioia

Tollard

Dubuc

et al.

Silent ischemic lesions in young adults with first stroke are associated with recurrent stroke. Neurology 2012; 79: 1208–1214.

20.

Debette

Beiser

DeCarli

et al.

Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality. Stroke 2010; 41: 600–606.

21.

Halkes

van Gijn

Kappelle

Koudstaal

Algra

. ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6: 115–124.

22.

De Schryver

Algra

Kappelle

van Gijn

Koudstaal

. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev 2012; 9: CD001342.

23.

Granger

Alexander

McMurray

et al.

Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011; 365: 981–992.

24.

Connolly

Eikelboom

Joyner

et al.

AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.

25.

Lee

Park

Shin

et al.

Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation. Eur Neurol 2010; 64: 193–200.

26.

Lindley

Wardlaw

Sandercock

et al.

Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis 2004; 13: 235–246.

27.

Álvarez-Sabín

Maisterra

Santamarina

Kase

. Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol 2013; 12: 689–705.

28.

Diener

Easton

Granger

et al.

RE-SPECT ESUS Investigators. Design of randomized, double-blind, evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke 2015; 10: 1309–1312.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB

0.57 MB